
WHAT IS CLAIMED IS:


1. A crystalline pharmaceutically acceptable salt of (*E*)-3-(4-((1*R*,3*R*)-2-(Bicyclo[1.1.1]pentan-1-yl)-3-methyl-2,3,4,9-tetrahydro-1*H*-pyrido[3,4-b]indol-1-yl)-3,5-difluorophenyl)acrylic acid (Compound A):



Compound A

wherein the crystalline pharmaceutically acceptable salt is a crystalline hydrosulfate salt of Compound A as Form A or a crystalline hydrosulfate salt of Compound A as Form C.

2. A crystalline pharmaceutically acceptable salt of (*E*)-3-(4-((1*R*,3*R*)-2-(Bicyclo[1.1.1]pentan-1-yl)-3-methyl-2,3,4,9-tetrahydro-1*H*-pyrido[3,4-b]indol-1-yl)-3,5-difluorophenyl)acrylic acid (Compound A):



Compound A

wherein the crystalline pharmaceutically acceptable salt is a crystalline sulfate salt of Compound A as Form A or a crystalline sulfate salt of Compound A as Form C.

3. A mixture of crystalline pharmaceutically acceptable salts of Compound A comprising a crystalline hydrosulfate salt of Compound A as Form A and a crystalline sulfate salt of Compound A as Form A; or a crystalline hydrosulfate salt of Compound A as Form C and a crystalline sulfate salt of Compound A as Form C.

4. The mixture of crystalline pharmaceutically acceptable salts of Claim 3, wherein the amount of the crystalline hydrosulfate salt of Compound A as Form A + the amount of the crystalline sulfate salt of Compound A as Form A is ≥ 85% of the mixture of crystalline pharmaceutically acceptable salt of Compound A, or the amount of the crystalline hydrosulfate

salt of Compound A as Form C + the amount of the crystalline sulfate salt of Compound A as Form C is ≥ 85% of the mixture of crystalline pharmaceutically acceptable salt of Compound A.

5. The crystalline pharmaceutically acceptable salt or the mixture of crystalline pharmaceutically acceptable salts of any one of Claims 1-4, wherein Form A is characterized by one or more peaks in an X-ray powder diffraction pattern, wherein the one or more peaks is selected from a peak in the range of from 9.4 degrees 2θ ± 0.2 degrees 2θ to 9.7 degrees 2θ ± 0.2 degrees 2θ, a peak in the range of from 10.2 degrees 2θ ± 0.2 degrees 2θ to 10.5 degrees 2θ ± 0.2 degrees 2θ and a peak in the range of from 10.9 degrees 2θ ± 0.2 degrees 2θ to 11.2 degrees 2θ ± 0.2 degrees 2θ.

6. The crystalline pharmaceutically acceptable salt or the mixture of crystalline pharmaceutically acceptable salts of any one of Claims 1-4, wherein Form A is characterized by one or more peaks in an X-ray powder diffraction pattern, wherein the one or more peaks is selected from a peak in the range of from 4.7 degrees 2θ ± 0.2 degrees 2θ to 5.0 degrees 2θ ± 0.2 degrees 2θ, a peak in the range of from 9.4 degrees 2θ ± 0.2 degrees 2θ to 9.7 degrees 2θ ± 0.2 degrees 2θ, a peak in the range of from 10.2 degrees 2θ ± 0.2 degrees 2θ to 10.5 degrees 2θ ± 0.2 degrees 2θ, a peak in the range of from 10.9 degrees 2θ ± 0.2 degrees 2θ to 11.2 degrees 2θ ± 0.2 degrees 2θ, a peak in the range of from 14.7 degrees 2θ ± 0.2 degrees 2θ to 15.0 degrees 2θ ± 0.2 degrees 2θ, a peak in the range of from 16.9 degrees 2θ ± 0.2 degrees 2θ to 17.2 degrees 2θ ± 0.2 degrees 2θ, a peak in the range of from 19.6 degrees 2θ ± 0.2 degrees 2θ to 19.9 degrees 2θ ± 0.2 degrees 2θ, and a peak in the range of from 20.9 degrees 2θ ± 0.2 degrees 2θ to 21.1 degrees 2θ ± 0.2 degrees 2θ.

7. The crystalline pharmaceutically acceptable salt or the mixture of crystalline pharmaceutically acceptable salts of any one of Claims 1-4, wherein Form A has an X-ray powder diffraction pattern spectrum corresponding to the representative XRPD spectrum depicted in Figure 1.

8. The crystalline pharmaceutically acceptable salt or the mixture of crystalline pharmaceutically acceptable salts of any one of Claims 1-4, wherein Form A is characterized by a differential scanning calorimetry (DSC) thermogram comprising an exotherm peak at 185 ºC ± 10% of 185 ºC.

9. The crystalline pharmaceutically acceptable salt or the mixture of crystalline pharmaceutically acceptable salts of any one of Claims 1-4, wherein Form A has a differential

scanning calorimetry (DSC) thermogram corresponding to the representative DSC thermogram depicted in Figure 2.

10. The crystalline pharmaceutically acceptable salt or the mixture of crystalline pharmaceutically acceptable salts of any one of Claims 1-4, wherein Form A is characterized by a thermal gravimetric analysis (TGA) thermogram corresponding to the representative TGA thermogram depicted in a figure selected from the group consisting of Figure 32A, Figure 32B, and Figure 34.

11. The crystalline pharmaceutically acceptable salt or the mixture of crystalline pharmaceutically acceptable salts of any one of Claims 1-4, wherein Form C is characterized by one or more peaks in an X-ray powder diffraction pattern, wherein the one or more peaks is selected from a peak in the range of from 9.0 degrees 2θ ± 0.2 degrees 2θ to 9.3 degrees 2θ ± 0.2 degrees 2θ, a peak in the range of from 9.8 degrees 2θ ± 0.2 degrees 2θ to 10.1 degrees 2θ ± 0.2 degrees 2θ and a peak in the range of from 14.1 degrees 2θ ± 0.2 degrees to 14.4 degrees 2θ ± 0.2 degrees 2θ

12. The crystalline pharmaceutically acceptable salt or the mixture of crystalline pharmaceutically acceptable salts of any one of Claims 1-4, wherein Form C is characterized by one or more peaks in an X-ray powder diffraction pattern, wherein the one or more peaks is selected from a peak in the range of from 4.4 degrees 2θ ± 0.2 degrees 2θ to 4.7 degrees 2θ ± 0.2 degrees 2θ, a peak in the range of from 7.2 degrees 2θ ± 0.2 degrees 2θ to 7.5 degrees 2θ ± 0.2 degrees 2θ, a peak in the range of from 9.0 degrees 2θ ± 0.2 degrees 2θ to 9.3 degrees 2θ ± 0.2 degrees 2θ, a peak in the range of from 9.8 degrees 2θ ± 0.2 degrees 2θ to 10.1 degrees 2θ ± 0.2 degrees 2θ, a peak in the range of from 10.2 degrees 2θ ± 0.2 degrees 2θ to 10.5 degrees 2θ ± 0.2 degrees 2θ, a peak in the range of from 11.4 degrees 2θ ± 0.2 degrees 2θ to 11.7 degrees 2θ ± 0.2 degrees 2θ, a peak in the range of from 13.5 degrees 2θ ± 0.2 degrees 2θ to 13.8 degrees 2θ ± 0.2 degrees 2θ, a peak in the range of from 14.1 degrees 2θ ± 0.2 degrees 2θ to 14.4 degrees 2θ ± 0.2 degrees 2θ, a peak in the range of from 17.7 degrees 2θ ± 0.2 degrees 2θ to 18.0 degrees 2θ ± 0.2 degrees 2θ, a peak in the range of from 18.1 degrees 2θ ± 0.2 degrees 2θ to 18.4 degrees 2θ ± 0.2 degrees 2θ, a peak in the range of from 19.7 degrees 2θ ± 0.2 degrees 2θ to 20.0 degrees 2θ ± 0.2 degrees 2θ, a peak in the range of from 20.5 degrees 2θ ± 0.2 degrees 2θ to 20.8 degrees 2θ ± 0.2 degrees 2θ and a peak in the range of from 22.2 degrees 2θ ± 0.2 degrees 2θ to 22.5 degrees 2θ ± 0.2 degrees 2θ.

13. The crystalline pharmaceutically acceptable salt or the mixture of crystalline pharmaceutically acceptable salts of any one of Claims 1-4, wherein Form C has an X-ray powder diffraction pattern corresponding to the representative XRPD spectrum depicted in Figure 5.

14. The crystalline pharmaceutically acceptable salt or the mixture of crystalline pharmaceutically acceptable salt of any one of Claims 1-4, wherein Form C is characterized by a differential scanning calorimetry (DSC) thermogram comprising an exotherm at 182 ºC ± 10% of 182 ºC.

15. The crystalline pharmaceutically acceptable salt or the mixture of crystalline pharmaceutically acceptable salts of any one of Claims 1-4, wherein Form C has a differential scanning calorimetry (DSC) thermogram corresponding to the representative DSC thermogram depicted in a figure selected from the group consisting of Figure 6A and Figure 6B.

16. The crystalline pharmaceutically acceptable salt or the mixture of crystalline pharmaceutically acceptable salts of any one of Claims 1-4, wherein Form C is characterized by a thermal gravimetric analysis (TGA) thermogram corresponding to the representative TGA thermogram depicted in Figure 6B.

17. A pharmaceutical composition comprising an effective amount of the crystalline pharmaceutically acceptable salt or the mixture of crystalline pharmaceutically acceptable salts of any one of Claims 1-16, and a pharmaceutically acceptable carrier, diluent, excipient or combination thereof.

18. Use of the crystalline pharmaceutically acceptable salt or the mixture of crystalline pharmaceutically acceptable salts of any one of Claims 1-16, or the pharmaceutical composition of Claim 17, in the manufacture of a medicament for the treatment of a disease or condition selected from the group consisting of a breast cancer and a gynecological cancer.

19. The use according to Claim 18, wherein the disease or condition is a breast cancer.

20. The use according to Claim 18, wherein the disease or condition is a gynecological cancer.